Denmark
January 18, 2017
Sales grew by 2% organically and by 1% in DKK, primarily driven by Agriculture & Feed and Technical & Pharma. The EBIT margin improved by 0.2 percentage points to 27.9%,
and EBIT grew by 2%. Net profit increased by 8%. In Q4, sales grew by 6% organicallyand by 8% in DKK compared with Q4 2015. The proposed dividend payout of DKK 4.0 per share is equivalent to dividend growth of 14% and a payout ratio of 39%.
In 2017, Novozymes expects to deliver organic sales growth of 2-5%, with contributions from all five business areas. We expect an EBIT margin of around 28% and a ROIC incl. goodwill of 24-25%. A new stock buyback program worth up to DKK 2 billion is planned.
Strategy: Novozymes sees long-term opportunities within industrial biotechnology and will continue to invest in innovation to realize the potential of its pipeline. Successful commercialization of the pipeline makes a return to historical organic sales growth rates achievable. Novozymes now allocates additional resources to high-growth opportunities, primarily in emerging markets, while safeguarding profitability. Unfortunately, this means that across the organization and geographies, we will lay off 198 employees on January 18-19, 2017, 62 of them in Denmark.
Peder Holk Nielsen, President & CEO of Novozymes, comments:
“Q4 came in as expected at 6% organic sales growth, marking a positive end to an otherwise challenging year. 2017 will be a year with sustained investments in new innovation. The divisions have reviewed their strategies and made significant changes to accelerate growth, for example shifting more resources to the emerging markets. As a consequence, we unfortunately need to lay off 198 employees to enable investments in market opportunities in both 2017 and 2018.”
Read the full announcement in PDF
Explore The Novozymes Report 2016 online
Topics
Species
